Machine Learning

With a new CEO known for billion-dollar deals, Modulari-T Biosciences is poised to commercialize its next-gen in vivo cell therapy platform.

The medtech giant posts Q1 growth and secures critical EU approvals for new devices, navigating post-pandemic shifts and geopolitical headwinds with strong cash flow.

The quant firm's AI-driven event strategy lands a key institutional partner, filling half of its $1B capacity and signaling a broader Wall Street shift.

Protos Security's latest acquisition signals a major industry shift, combining nationwide guarding with elite global intelligence and executive protection.

As AI tools strain developer infrastructure, Eclipse offers enterprise-grade reliability to AWS and Google, ensuring the VS Code ecosystem remains open.

With the appointment of Mike Cavan, Quest Analytics signals a major push to dominate the provider network space by leveraging deep data analytics expertise.

A UK biotech's Rincell-1 therapy enters human trials, aiming to regenerate auditory nerves and restore hearing where current technology falls short.

With £21M in funding, new Focused Research Organizations, Meridial and Echo Labs, aim to tackle major bottlenecks in neuroscience and ecological intelligence.

A novel drug candidate from Addex Therapeutics shows robust cough suppression in key preclinical studies, offering hope for a treatment without current side effects.

The software giant joins the CHERI Alliance and lands a UK contract to bring hardware-enforced memory protection to mission-critical RISC-V systems.

At Money20/20, EurewaX launched its Payment Platform as a Service, aiming to empower Asian firms with rapid, AI-driven global payment capabilities.

With a fresh $60 million IPO, JATT II is targeting the next wave of healthcare innovators using AI and machine learning to revolutionize drug discovery.

With a $719M war chest from its blockbuster IPO, Kailera Therapeutics is poised to challenge the dominance of Lilly and Novo in the lucrative obesity market.

A novel 'payload-bearing' drug shows potent preclinical activity against a rare pediatric cancer, paving an accelerated path to human trials.

As IPO markets revive, advisory firms say patient private equity capital and rigorous prep are the keys for companies hoping to go public successfully.

Australian GRC leader Protecht buys US-based VISO TRUST, integrating advanced AI to automate security and dominate the rapidly expanding risk management market.

The new SGRD fund offers investors a targeted play on the multi-billion dollar overhaul of global electricity grids, a critical, overlooked sector.

With backing from Mayo Clinic, a startup's AI promises to slash biomarker analysis from weeks to minutes, accelerating cancer care and drug discovery.

SiMa.ai's Modalix SoM wins a major industry award, signaling a shift in the edge AI market toward power-efficient, on-device generative AI.

At Harvard, a Chinese firm's 'Strategic Product' model is gaining acclaim. See how Kmind Consulting's human-centric approach is fueling global hits.